Document is current
Any future updates will be listed below
-
Authors
Shash, Emad https://orcid.org/0000-0002-2133-9578
Sebaie, Medhat El
Youssef, Omar
Anter, Nagwan
Hegazy, Ahmed
Naoum, Rana
Abdelrahman, Mohamed
Galal, Hend
Mahfouz, Ayatallah
Affify, Alia
Montasser, Maram
Ahmed, Asmaa
Eid, Reem
Bektash, Fatma
- License Information
-
More Information
Article History
Received: 23 January 2026
Accepted: 22 February 2026
First Online: 31 March 2026
Declarations
:
: Not applicable for this methodology manuscript as no new participant-level data are presented. Associated evaluations were conducted under institutional governance and approvals as reported previously.
: No other relevant financial or non-financial interests to disclose.
: Not applicable.
: The remaining authors declare no competing interests.
: Emad Shash: Advisory Boards/Consultancy/Speaker's Bureau: Engagements with Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Clinart MENA, Genomics Genetics, GSK, Hikma, EVA Pharma, Janssen, Lilly, MSD, Mundipharma, Newbridge Pharmaceutical, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz. Travel Grants: Received from Boehringer Ingelheim, Hikma, Janssen, Lilly, MSD, Mundipharma, Novartis, Pfizer, Roche. Clinical Trials Involvement: Participated in clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Roche.Fatma Bektash, and Asmaa El-Sayed: Each has been engaged in paid workshop activity by Roche.
